UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2012

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION
(Translation of registrant’s name into English)

48^th Floor, Bank of China Tower
1 Garden Road
Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F xForm 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.

EXPLANATORY NOTE

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or China Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date this Report on Form 6-K is filed, and the Company does not intend to update any of the forward-looking statements after the date this Report on Form 6-K is filed to confirm these statements to actual results, unless required by law.

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC; changing legislation or regulatory environments in the PRC; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission.

Results of Operations and Financial Condition

Following this cover page are the preliminary unaudited consolidated financial results for the three months and year ended March 31, 2012 of the Company.

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31, 2011 and 2012

	March 31,		March 31,
	2011		2012
	RMB		RMB		US$
	(in thousands except share data)
ASSETS
Current assets
Cash and cash equivalents		611,387		794,311		126,131
Accounts receivable, less allowance for doubtful accounts
(March 31, 2011: RMB11,850; March 31, 2012: RMB13,916)		77,402		79,012		12,546
Inventories		6,729		6,666		1,059
Prepaid expenses and other receivables		9,982		11,561		1,836
Trading securities		-		354		56
Deferred tax assets		5,373		5,268		837
Total current assets		710,873		897,172		142,465
Property, plant and equipment, net		250,348		267,862		42,535
Non-current prepayments		5,752		2,863		455
Non-current accounts receivable, less allowance for doubtful accounts
(March 31, 2011: RMB28,106; March 31, 2012: RMB38,628)		240,952		254,236		40,371
Inventories		31,600		34,651		5,502
Intangible assets, net		134,412		129,791		20,610
Available-for-sale equity securities		52,733		98,199		15,593
Other investments		134,363		134,363		21,336
Deferred tax assets		2,565		5,013		796
Total assets		1,563,598		1,824,150		289,663
LIABILITIES
Current liabilities
Bank loan		45,000		45,000		7,146
Accounts payable		5,046		6,343		1,007
Accrued expenses and other payables		106,731		33,351		5,296
Deferred revenue		82,319		106,110		16,850
Amounts due to related party		360		360		57
Income tax payable		11,156		5,943		944
Total current liabilities		250,612		197,107		31,300
Deferred revenue		162,668		306,534		48,676
Other non-current liabilities		30,036		60,420		9,594
Deferred tax liabilities		26,890		24,462		3,884
Total liabilities		470,206		588,523		93,454

EQUITY
Shareholders’ equity
Ordinary shares - US$0.0001 par value, 250,000,000 shares authorized, 75,406,875 shares and 73,140,147 shares issued and outstanding as of March 31, 2011, and 2012, respectively	52		50	8
Additional paid-in capital	910,316		865,654	137,460
Accumulated other comprehensive (loss)/ income	(18,580	)	26,057	4,138
Retained earnings	178,993		310,973	49,380
Total shareholders’ equity	1,070,781		1,202,734	190,986
Non-controlling interests	22,611		32,893	5,223
Total equity	1,093,392		1,235,627	196,209
Total liabilities and equity	1,563,598		1,824,150	289,663

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months and Year ended March 31, 2011 and 2012

	Three months ended March 31,									Year ended March 31,
	2011			2012						2011			2012
	RMB			RMB			US$			RMB			RMB			US$
	(in thousands except per share)
Revenues		94,671			99,778			15,844			339,532			380,490			60,419
Direct costs		(20,001	)		(23,330	)		(3,705	)		(77,376	)		(86,658	)		(13,761	)
Gross profit		74,670			76,448			12,139			262,156			293,832			46,658
Operating expenses
Research and development		(1,717	)		(1,953	)		(310	)		(6,960	)		(7,615	)		(1,209	)
Sales and marketing		(13,273	)		(16,567	)		(2,631	)		(47,583	)		(61,678	)		(9,794	)
General and administrative		(23,251	)		(23,086	)		(3,666	)		(83,794	)		(89,696	)		(14,243	)
Total operating expenses		(38,241	)		(41,606	)		(6,607	)		(138,337	)		(158,989	)		(25,246	)
Operating income		36,429			34,842			5,532			123,819			134,843			21,412
Other income, net
Interest income		2,694			3,411			542			9,065			13,432			2,133
Interest expense		(657	)		(896	)		(142	)		(2,606	)		(3,287	)		(522	)
Exchange (loss)/ gain		(61	)		33			5			486			(1,343	)		(213	)
Dividend income		-			-			-			-			7,217			1,146
Others		269			823			131			1,378			737			117
Total other income, net		2,245			3,371			536			8,323			16,756			2,661
Income before income tax		38,674			38,213			6,068			132,142			151,599			24,073
Income tax expense		(10,867	)		(6,597	)		(1,048	)		(33,929	)		(9,634	)		(1,530	)
Net income		27,807			31,616			5,020			98,213			141,965			22,543
Income attributable to non-controlling interests		(1,548	)		(2,377	)		(377	)		(6,510	)		(9,985	)		(1,586	)
Net income attributable to shareholders		26,259			29,239			4,643			91,703			131,980			20,957
Net income per share:
Attributable to ordinary shares
-Basic		0.35			0.40			0.06			1.31			1.79			0.28
-Diluted		0.35			0.40			0.06			1.31			1.79			0.28

Other Events

On June 11, 2012, the Company issued a press release announcing preliminary unaudited consolidated financial results for the three months and year ended March 31, 2012. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.	Description
99.1	Press Release, dated June 11, 2012
101	The following financial statements as of and for the three months period and year ended March 31, 2012, from China Cord Blood Corporation’s Report of Foreign Private Issuer on Form 6-K for the month of June 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) the unaudited condensed consolidated balance sheets; and (ii) the unaudited condensed consolidated statements of operations.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHINA CORD BLOOD CORPORATION
By:	/s/ Albert Chen
Name:	Albert Chen
Title:	Chief Financial Officer

Dated: June 11, 2012